Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winnerBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6702 (Published 09 December 2015) Cite this as: BMJ 2015;351:h6702
- Michael McCarthy
A systematic review comparing the safety and efficacy of five once weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) has found no clear winner for treating type 2 diabetes.
The findings, published in the Annals of Internal Medicine,1 emphasised the need for trials that directly compare these drugs to identify their relative benefits and harms, the researchers wrote.
GLP-1RAs are relatively new injectable drugs that stimulate insulin secretion, inhibit glucagon secretion, slow gastric emptying, and reduce food intake. They have been shown to improve glucose control and reduce body weight and are currently recommended by the American Diabetes Association and the European Association for the Study of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial